Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are willing to take part and agree to sign a consent form
- People who have been diagnosed with a specific type of blood cancer called diffuse large B-cell lymphoma (DLBCL), confirmed by a laboratory test, and whose cancer cells carry a marker called CD20
- People whose lymphoma has come back or stopped responding to treatment, and who have already tried at least 2 standard treatment plans — including treatments that contained a type of chemotherapy called anthracyclines and a CD20-targeting drug — or who have had a stem cell transplant using their own cells
- People who have at least one area of lymphoma that can be measured on a CT or PET scan
- People who are generally well enough to carry out light activity and care for themselves (assessed using a standard medical scale — confirm with trial site)
- People whose heart, liver, kidneys, and other organs are functioning at a sufficient level
- People who have suitable veins to allow a blood collection procedure called apheresis
- Women who could become pregnant must agree to use effective contraception for one year after receiving the treatment
- Men who have not had a vasectomy and who are sexually active with women who could become pregnant must agree to use barrier contraception for one year after receiving the treatment
Who may not be able to join:
- People whose lymphoma started in the brain or spinal cord
- People who have been diagnosed with another cancer within the past 2 years
- People with an active infection of hepatitis B, hepatitis C, HIV, or syphilis
- People who have had a serious blood clot in a deep vein or in the lungs within the past 3 months
- People who have been treated with blood-thinning medication (other than for prevention) due to a serious blood clot in the past 3 months
- People with an active infection that is not under control
- People who have a condition called graft-versus-host disease, whether ongoing or long-term
- People who have had a serious heart condition within the past 6 months
- People who have had a serious condition affecting the brain or nervous system within the past 6 months
- Women who are pregnant or breastfeeding
- People who have not completed the required waiting period before the blood collection procedure (confirm with trial site)
- People who the trial doctor believes may not be able or willing to follow the trial requirements, or who may not be suitable for another reason
- People who have previously received any gene-modified T-cell therapy or other cell and gene therapies
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rong Tao, MD, Fudan University
Phone: +8621-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of dose-limiting toxicities (DLTs); AE/SAE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.